• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

LRP1B 与免疫细胞浸润相关，影响结直肠癌患者免疫治疗的疗效。

LRP1B associated with immune cell infiltration influenced the efficacy of immunotherapy in colorectal cancer patients.

机构信息

Department of Gastrointestinal Surgery, The Yue Bei People's Hospital of Shaoguan, No. 133, Huimin South Road, Shaoguan, Guangdong 512026, China.

Department of Gastrointestinal Surgery, The Yue Bei People's Hospital of Shaoguan, No. 133, Huimin South Road, Shaoguan, Guangdong 512026, China.

出版信息

Clinics (Sao Paulo). 2024 Nov 11;79:100516. doi: 10.1016/j.clinsp.2024.100516. eCollection 2024.

DOI:10.1016/j.clinsp.2024.100516
PMID:39532036
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11599987/
Abstract

OBJECTIVE

Colorectal cancer is one of the most common malignant tumors in the world, which seriously threatens human health. It is essential for the search for new oncogene targets in colorectal cancer.

METHODS

Samples from 57 colorectal cancer patients were collected in this study. Next-Generation Sequencing (NGS) was performed to detect gene mutation, assess Microsatellite Instability (MSI), and evaluate Tumor Mutational Burden (TMB). RNA data from 528 CRC patients from the TCGA database were analyzed.

RESULTS

A total of 57 colon cancer patients were included in this study, including 30 males and 27 females, with a mean age of 56 years. In this study, the most common mutations were APC (79 %), TP53 (61 %), TTN (48 %), KRAS (42 %), SYNE1 (28 %), MUC16 (25 %), PIK3CA (25 %), FAT4 (22 %), RYR2 (19 %), OBSCN (18 %), and ZFHX4 (18 %). Subsequently, the authors analyzed gene mutations in colorectal cancer patients according to gender, age, and TMB status. Significant differences in immune cell infiltration were found between colorectal cancer tissues and normal tissues by CIBERSORT analysis. LRP1B may serve as a potential colorectal cancer therapeutic target, and its absence leads to changes in immune cell infiltration.

CONCLUSION

The authors described the molecular characteristics of CRC. Loss of LRP1B leads to changes in immune cell infiltration and can be used as a therapeutic target for colorectal cancer.

摘要

目的

结直肠癌是世界上最常见的恶性肿瘤之一，严重威胁人类健康。寻找结直肠癌新的癌基因靶点至关重要。

方法

本研究收集了 57 例结直肠癌患者的样本。采用下一代测序（NGS）检测基因突变、评估微卫星不稳定性（MSI）和评估肿瘤突变负担（TMB）。对 TCGA 数据库中 528 例 CRC 患者的 RNA 数据进行分析。

结果

本研究共纳入 57 例结肠癌患者，其中男性 30 例，女性 27 例，平均年龄 56 岁。在本研究中，最常见的突变是 APC（79%）、TP53（61%）、TTN（48%）、KRAS（42%）、SYNE1（28%）、MUC16（25%）、PIK3CA（25%）、FAT4（22%）、RYR2（19%）、OBSCN（18%）和 ZFHX4（18%）。随后，作者根据性别、年龄和 TMB 状态分析了结直肠癌患者的基因突变。CIBERSORT 分析发现结直肠癌组织和正常组织之间的免疫细胞浸润存在显著差异。LRP1B 可能是潜在的结直肠癌治疗靶点，其缺失导致免疫细胞浸润发生变化。

结论

作者描述了结直肠癌的分子特征。LRP1B 的缺失导致免疫细胞浸润发生变化，可作为结直肠癌的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a27/11599987/89d5987eb2f8/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a27/11599987/b8e17babc181/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a27/11599987/da2f6ea5dd0e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a27/11599987/176cf4c631a5/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a27/11599987/2a5eef4076e1/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a27/11599987/89d5987eb2f8/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a27/11599987/b8e17babc181/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a27/11599987/da2f6ea5dd0e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a27/11599987/176cf4c631a5/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a27/11599987/2a5eef4076e1/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a27/11599987/89d5987eb2f8/gr5.jpg

相似文献

1
LRP1B associated with immune cell infiltration influenced the efficacy of immunotherapy in colorectal cancer patients.LRP1B 与免疫细胞浸润相关，影响结直肠癌患者免疫治疗的疗效。
Clinics (Sao Paulo). 2024 Nov 11;79:100516. doi: 10.1016/j.clinsp.2024.100516. eCollection 2024.
2
Certain pMMR colorectal cancer patients should undergo additional MSI-PCR testing to reduce the risk of misdiagnosing MSI-H and Lynch syndrome.某些错配修复功能完整（pMMR）的结直肠癌患者应接受额外的微卫星不稳定性聚合酶链反应（MSI-PCR）检测，以降低误诊为微卫星高度不稳定（MSI-H）和林奇综合征的风险。
BMC Cancer. 2025 Jul 1;25(1):1103. doi: 10.1186/s12885-025-14484-3.
3
Exploring potential therapeutic targets for colorectal tumors based on whole genome sequencing of colorectal tumors and paracancerous tissues.基于结直肠癌及癌旁组织全基因组测序探索结直肠癌潜在治疗靶点
Front Mol Biosci. 2025 Jul 4;12:1605117. doi: 10.3389/fmolb.2025.1605117. eCollection 2025.
4
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.液体活检能否通过低深度全基因组测序检测肉瘤患者的循环肿瘤DNA？一项初步评估。
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
5
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
6
Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study.早发性结直肠癌患者的基因组突变模式：一项国际多队列观察性研究
Lancet Oncol. 2025 Aug;26(8):1055-1066. doi: 10.1016/S1470-2045(25)00239-6. Epub 2025 Jul 3.
7
Identifying CDCA4 as a Radiotherapy Resistance-Associated Gene in Colorectal Cancer by an Integrated Bioinformatics Analysis Approach.通过综合生物信息学分析方法鉴定CDCA4为结直肠癌放疗抵抗相关基因。
Genes (Basel). 2025 Jun 9;16(6):696. doi: 10.3390/genes16060696.
8
ctDNA-guided adjuvant immunotherapy in colorectal cancer.ctDNA 引导的结直肠癌辅助免疫治疗
Immunotherapy. 2024;16(20-22):1197-1202. doi: 10.1080/1750743X.2024.2430941. Epub 2024 Nov 17.
9
KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis.成人转移性结直肠癌肿瘤的KRAS突变检测：一项系统评价与成本效益分析
Health Technol Assess. 2014 Oct;18(62):1-132. doi: 10.3310/hta18620.
10
Oncolytic reovirus enhances the effect of CEA immunotherapy when combined with PD1-PDL1 inhibitor in a colorectal cancer model.在结直肠癌模型中，溶瘤呼肠孤病毒与PD1-PDL1抑制剂联合使用时可增强CEA免疫疗法的效果。
Immunotherapy. 2025 Apr;17(6):425-435. doi: 10.1080/1750743X.2025.2501926. Epub 2025 May 12.

本文引用的文献

1
Diagnostic Accuracy of Highest-Grade or Predominant Histological Differentiation of T1 Colorectal Cancer in Predicting Lymph Node Metastasis: A Systematic Review and Meta-Analysis.T1 结直肠癌最高级别或主要组织学分化预测淋巴结转移的诊断准确性：系统评价和荟萃分析。
Clin Transl Gastroenterol. 2024 Mar 1;15(3):e00673. doi: 10.14309/ctg.0000000000000673.
2
Advancements in endoscopic management of small-bowel polyps in Peutz-Jeghers syndrome and familial adenomatous polyposis.黑斑息肉综合征和家族性腺瘤性息肉病中小肠息肉内镜治疗的进展
Therap Adv Gastroenterol. 2023 Dec 30;17:17562848231218561. doi: 10.1177/17562848231218561. eCollection 2024.
3
Shenling Baizhu Decoction (SLBZD) may play a synergistic role of tirelizumab in the treatment of colorectal cancer by influencing the imbalance of colon flora and Tumor microenvironment.
参苓白术汤可能通过影响结肠菌群和肿瘤微环境的失衡，在替雷利珠单抗治疗结直肠癌中发挥协同作用。
J Cancer. 2024 Jan 1;15(1):30-40. doi: 10.7150/jca.88854. eCollection 2024.
4
The feedback loop of EFTUD2/c-MYC impedes chemotherapeutic efficacy by enhancing EFTUD2 transcription and stabilizing c-MYC protein in colorectal cancer.EFTUD2/c-MYC 反馈环通过增强 EFTUD2 转录和稳定结直肠癌中的 c-MYC 蛋白来阻碍化疗疗效。
J Exp Clin Cancer Res. 2024 Jan 2;43(1):7. doi: 10.1186/s13046-023-02873-0.
5
CRNDE: A Pivotal Oncogenic Long Non-Coding RNA in Cancers.CRNDE：癌症中关键的致癌长非编码 RNA。
Yale J Biol Med. 2023 Dec 29;96(4):511-526. doi: 10.59249/VHYE2306. eCollection 2023 Dec.
6
Serum copper status of patients with colorectal cancer: A systematic review and meta-analysis.结直肠癌患者血清铜水平：系统评价和荟萃分析。
J Trace Elem Med Biol. 2024 Mar;82:127370. doi: 10.1016/j.jtemb.2023.127370. Epub 2023 Dec 20.
7
Mitochondrial fusion-fission dynamics and its involvement in colorectal cancer.线粒体融合-裂变动力学及其在结直肠癌中的作用。
Mol Oncol. 2024 May;18(5):1058-1075. doi: 10.1002/1878-0261.13578. Epub 2024 Jan 9.
8
Benchmarking mismatch repair testing for patients with cancer receiving immunotherapy.对接受免疫疗法的癌症患者进行错配修复检测的基准测试。
Cancer Cell. 2024 Jan 8;42(1):6-7. doi: 10.1016/j.ccell.2023.12.001. Epub 2023 Dec 28.
9
Research progress of biomineralization for the diagnosis and treatment of malignant tumors.生物矿化在恶性肿瘤诊断与治疗中的研究进展
Front Pharmacol. 2023 Dec 14;14:1335019. doi: 10.3389/fphar.2023.1335019. eCollection 2023.
10
RTKN2 knockdown alleviates the malignancy of breast cancer cells by regulating the Wnt/β-catenin pathway.RTKN2 knockdown 通过调控 Wnt/β-catenin 通路缓解乳腺癌细胞的恶性表型。
Sci Rep. 2023 Dec 27;13(1):23023. doi: 10.1038/s41598-023-50153-w.